Mercier B, Dreano L, Neveu E, Estrade F, et al. Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy. Ann Nucl Med 2026 May 23. doi: 10.1007/s12149-026-02236.
PMID: 42176106